Extra radiation boost for advanced lung cancer after standard treatment
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding a precise, high-dose radiation boost (CyberKnife) after standard chemoradiation can improve outcomes for people with stage III non-small cell lung cancer that cannot be surgically removed. It is for those who have already completed two cycles of induction chemo and at least 40 Gy of radiation with chemo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have stage III non-small cell lung cancer that cannot be surgically removed
- You have already received two cycles of chemotherapy followed by at least 40 Gy of radiation with additional chemo
- Your tumors are small enough (less than 5 cm across) and limited to 1–3 spots for a precise radiation boost
- You are well enough to be active (ECOG score 0–2)
- You do not have a specific EGFR gene mutation
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, JNJ-90301900, given together with standard chemotherapy and radiation, followed by maintenance immunotherapy (durvalumab) for people with stage 3 non-small cell lung cancer that cannot be surgically removed. The goal is to see if adding this drug improves outcomes.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests whether adding high-dose, targeted radiation to the usual treatment helps people with locally advanced, non-operable lung cancer live longer or better control the cancer. It may help shrink tumors in the chest and improve outcomes when surgery can’t be done.
This trial studies how safe CyberKnife is when used to treat some borderline resectable or locally advanced pancreatic cancers after chemotherapy. It may help patients by targeting the tumor with precise radiation, while researchers closely watch for side effects.
This trial tests a new approach for advanced non-small cell lung cancer that cannot be surgically removed. It combines a focused, high-dose radiation treatment to the tumor core followed by standard chemotherapy and radiation together. This may help fight the cancer more effectively.
This trial is for people with advanced non-small cell lung cancer whose tumors responded well to initial chemo-immunotherapy. Instead of giving full chest radiation, doctors will only target the main tumor to see if it can prevent regrowth with fewer side effects.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.